glp-1 weight loss drug news today october 2025 Rhode Island considers ending Medicaid coverage of drugs for • Rhode Island Current GLP-1 Weight Loss Drug Market

The phase III SURMOUNT-3 trial by Thomas et al207 evaluated tirzepatide use following intensive lifestyle interventions

Neuroprotective Effects of GLP-1 Receptor Agonists in Neurodegenerative Disorders: A Large-Scale Propensity-Matched Cohort Study

While these results are promising, they should be viewed as preliminary given the modest strength of the available evidence

Those that do may see weight loss of 10% or more in a few months, and, if combined with a programme that helps you make long-term changes to your lifestyle, that weight loss can be greaterand can last far longer than weight-loss achieved through the usual fad diets

Adapted from Jastreboff et al

Understanding their differences can help determine which is most effective for individual health goals